• G.MEENA
• Dr.V.Aravamudhan

The Buyback is being undertaken by the Company in accordance with the provisions of Article 13 of the Articles of Association of the Company, the provisions of Sections 68, 69 and 70 of the Companies Act, 2013 and all other applicable provisions, if any, of the Act, the Companies (Share Capital and Debentures) Rules, 2014, to the extent applicable, and in compliance with the Buyback Regulations. The Buyback has been duly authorized by a resolution passed by the Board of Directors at their meeting held on June 23, 2016. Since the Buyback Size is less than 10% (ten percent) of the paid-up capital and free reserves (including securities premium account) of the Company under the board of directors approval route, as provided under the proviso to Section 68(2)(b) of the Companies Act, 2013, the approval of the Equity Shareholders of the Company is not required The Buyback is subject to such other approvals, permissions and sanctions as may be required from any statutory, regulatory or governmental authorities as may be required under applicable laws and is subject to such conditions and modifications, if any, as may be prescribed or imposed by such authorities while granting such approvals, permissions and sanctions, as may be required and which may be agreed to by the Board or any person authorized by the Board in this regard.

Buyback, pharmaceutical sector, regulations, roles etc.,

"ROLE OF PHARMACEUTICAL SECTOR IN BUYBACK OF SHARES", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.5, Issue 9, page no.570-576, September-2018, Available :http://www.jetir.org/papers/JETIR1809728.pdf

"ROLE OF PHARMACEUTICAL SECTOR IN BUYBACK OF SHARES", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.5, Issue 9, page no. pp570-576, September-2018, Available at : http://www.jetir.org/papers/JETIR1809728.pdf